Haemonetics Corporation

HAE · NYSE · Stock · Healthcare
$121.11
-0.50% today
Delayed price,

What Haemonetics does

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.

Key facts

Sector
Healthcare
Industry
Medical Devices
Market cap
$5.51B
P/E (ttm)
58.8
Forward P/E
21.0
Dividend yield
0.00%
Beta
0.61
Profit margin
7.1%
Employees
3,009
Headquarters
Boston, MA, United States
Exchange
NYSE

Performance

1 Month
+11.7%
3 Months
+55.5%
6 Months
+96.5%
1 Year
+141.0%
5 Years
+136.3%
$48.6252-week range$123.77
Biggest setback — last 12 months
-35.6%
1 Dec 2025 → 23 Mar 2026
Fell from $83.94 to $54.04 — its sharpest sustained decline this year.
Biggest run-up — last 12 months
+142.2%
27 Oct 2025 → 12 Oct 2026
Ran from $50.01 to $121.11 — its strongest sustained advance this year.

Price outlook — trend & volatility model

▲ Trend: Uptrend
Price is above its 20-, 50- and 200-day averages, each stacked above the next — a classic technical uptrend structure.
HorizonBear case (−1σ)Base caseBull case (+1σ)
1 Month$105.32 (-13.0%)$121.11$139.26 (+15.0%)
3 Months$95.09 (-21.5%)$121.11$154.26 (+27.4%)
6 Months$86.02 (-29.0%)$121.11$170.52 (+40.8%)
12 Months$74.65 (-38.4%)$121.11$196.48 (+62.2%)
Statistical, not machine-learning: a random-walk (no assumed drift) volatility model built from this ticker's own realized price history, plus a purely descriptive moving-average trend read. Illustrative only — not a price target and not financial advice. The bear and bull cases sit one standard deviation (1σ) below and above today's price, a range that covers about 68% of the outcomes the model treats as plausible, not a 68% chance of either case. Annualized volatility used: 48.4%, blended from this ticker's own 3-month and 1-year realized price history. Base case is deliberately flat — this quantifies a possible range, not a directional prediction. See the full model, including wider (≈95%) bands →

Comparable companies

Recent headlines

Recent insider activity

Acquired 2,538 shares — Madaus Martin D, Director · 2026-07-28
Acquired 2,538 shares — Zane Ellen M, Director · 2026-07-28
Acquired 2,538 shares — Pomeroy Claire, Director · 2026-07-28
Acquired 2,538 shares — KROLL MARK W, Director · 2026-07-28
Acquired 2,538 shares — Johnson Lloyd Emerson, Director · 2026-07-28
Source: SEC Form 4 filings. An "acquired" entry with no price is typically a stock award or option exercise rather than an open-market purchase. Search all insider trades →

Learn the basics

Prices and company data are delayed reference figures from public sources (Yahoo Finance, SEC EDGAR) and may be inaccurate or out of date. This page is informational only — it is not investment advice or a recommendation to buy or sell any security. Past performance does not indicate future results.